+

WO2007010946A1 - Inhibiteur de la proliferation de cellules synoviales - Google Patents

Inhibiteur de la proliferation de cellules synoviales Download PDF

Info

Publication number
WO2007010946A1
WO2007010946A1 PCT/JP2006/314287 JP2006314287W WO2007010946A1 WO 2007010946 A1 WO2007010946 A1 WO 2007010946A1 JP 2006314287 W JP2006314287 W JP 2006314287W WO 2007010946 A1 WO2007010946 A1 WO 2007010946A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell proliferation
synovial cell
flavopiridol
synovial
arthritis
Prior art date
Application number
PCT/JP2006/314287
Other languages
English (en)
Japanese (ja)
Inventor
Hitoshi Kosaka
Nobuyuki Miyasaka
Original Assignee
National University Corporation Tokyo Medical And Dental University
Riken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation Tokyo Medical And Dental University, Riken filed Critical National University Corporation Tokyo Medical And Dental University
Publication of WO2007010946A1 publication Critical patent/WO2007010946A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a synovial cell proliferation inhibitor comprising as an active ingredient at least one of flavopiridol (flavopiridol or IUPAC name: alvocidib) and a pharmaceutically acceptable salt thereof.
  • the present invention also relates to a pharmaceutical composition containing the synovial cell proliferation inhibitor and a treatment method using the synovial cell proliferation inhibitor.
  • synovial membrane is originally composed of a single layer of synovial cells.
  • the synovial cells may proliferate excessively due to some inflammatory mechanism, resulting in synovial hyperplasia.
  • synovial cells are activated in the increased synovium, and various inflammatory mediators and tissue destructive proteolytic enzymes are produced from the synovial cells.
  • This series of inflammatory reactions is referred to as proliferative synovitis, and as a result of the proliferative synovitis, there is a serious dysfunction such as cartilage degeneration or bone tissue destruction.
  • diseases in which such synovial cell proliferation is involved in the pathology for example, rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout and the like are known.
  • Rheumatoid arthritis is an autoimmune disease, and inflammatory mediators (eg, IL-1, IL-6, TNF-a, etc.) of lymphocyte isotropic force are excessively present in the vicinity of the joint. Is a disease in which inflammation and bone destruction of the tissue progress and a pathological condition appears. As one of the etiological factors, proliferation of the synovial cells is cited. However, since it is thought that there are a plurality of etiological factors, a multifaceted treatment method is required. Drug development is desired.
  • inflammatory mediators eg, IL-1, IL-6, TNF-a, etc.
  • symptomatic treatment has been carried out by administering an analgesic and an anti-inflammatory agent.
  • an analgesic and an anti-inflammatory agent.
  • symptomatic treatment although the onset can be delayed, It was impossible to stop the progression and even cure the disease itself.
  • synovial cell proliferation inhibitor examples include diterpene compounds (see Patent Document 1), FADD gene (Patent Document 1) that suppress synovial cell proliferation by inducing apoptosis of synovial cells. 2), Fas ligand (see Patent Document 3), anti-Fas antibody (see Patent Document 4), and 3,6-anhydrogalactose and its derivatives (see Patent Document 5), etc.
  • As an inhibitor of proliferation of synovial cells by inhibiting adhesion imidazole derivatives (see Patent Document 6), quinoline derivatives, quinolone derivatives (see Patent Document 7), and the like have been proposed.
  • the synovial cell proliferation inhibitor includes an association product of hyaluronic acid and zinc (see Patent Document 8), a quinolonecarboxylic acid derivative (see Patent Document 9), and a substance in milk whey protein (Patent Document 10).
  • BFGF antagonist see patent document 11
  • IL 6 antagonist see patent document 12
  • cAMP derivative see patent document 13
  • vitamin D3 and its derivatives see patent document 14
  • c-erbB-2 activity inhibition Agents see Patent Document 15
  • y-secretase-like protease inhibitors Patent Document 16
  • synovial cell proliferation inhibitors are used not only for rheumatoid arthritis, but also for prevention of the onset of diseases involving the proliferation of synovial cells such as osteoarthritis, psoriatic arthritis, and gout. It is expected to be a useful substance for controlling aging.
  • synovial cell growth inhibitor that can suppress the proliferation of synovial cells without rubbing, and a medicinal composition and a treatment method for treating a disease involving synovial cell proliferation without reducing resistance to infection are still available. It has been discovered and the current situation is.
  • Patent Document 1 Japanese Patent Application Laid-Open No. 2004-168713
  • Patent Document 2 JP 2000-198737 A
  • Patent Document 3 Japanese Patent Laid-Open No. 11-060501
  • Patent Document 4 Japanese Patent Laid-Open No. 08-208515
  • Patent Document 5 WO99Z064424
  • Patent Document 6 Japanese Unexamined Patent Publication No. 2003-040888
  • Patent Document 7 Japanese Unexamined Patent Publication No. 2002-371078
  • Patent Document 8 Japanese Patent Laid-Open No. 2003-089647
  • Patent Document 9 Japanese Patent Laid-Open No. 2002-293745
  • Patent Document 10 Japanese Patent Laid-Open No. 2001-011094
  • Patent Document 11 Japanese Unexamined Patent Publication No. 2000-229883
  • Patent Document 12 Japanese Patent Laid-Open No. 08-208514
  • Patent Document 13 Japanese Patent Application Laid-Open No. 07-324035
  • Patent Document 14 Japanese Patent Application Laid-Open No. 07-145062
  • Patent Document 15 WO0lZ076630
  • Patent Document 16 WO0lZ072321
  • An object of the present invention is to meet the above-mentioned demand, solve the conventional problems, and achieve the following objects. That is, the present invention provides a synovial cell proliferation inhibitor capable of suppressing the proliferation of synoviocytes without inducing apoptosis and causing immune suppression, and also has resistance to infection. It is an object of the present invention to provide a medicinal composition and a method for treating a disease involving synovial cell proliferation without reducing it.
  • flavopiridol flavopiridol or IUPAC name: alvocidib
  • flavopiridol flavopiridol or IUPAC name: alvocidib
  • Flavopyridol is a flavonoid that induces apoptosis against cancer cells, Dysoxylum binectariferum from the mahogany family, and a novel flavonoid synthesized with hints of components extracted from crusts. Its physiological activity is cyclin. Dependent kinase inhibitory activity, smooth muscle growth inhibitory activity, etc. are known!
  • the present invention is based on the above findings by the present inventors, and means for solving the above problems are as follows. That is,
  • flavopiridol flavopiridol or IUPAC name: alvocidib
  • alvocidib a compound represented by the following structural formula (1)
  • a pharmaceutically acceptable salt thereof as an active ingredient. It is a synovial cell proliferation inhibitor.
  • a medicinal composition comprising at least the synovial cell proliferation inhibitor according to ⁇ 1>.
  • ⁇ 3> The medicinal composition according to ⁇ 2> comprising a pharmaceutically acceptable carrier.
  • ⁇ 4> The medicinal composition according to any one of ⁇ 2> to ⁇ 3>, wherein at least one of anti-rheumatoid arthritis, anti-osteoarthritis, anti-psoriatic arthritis, and anti-gout is at least It is.
  • ⁇ 5> The medicinal composition according to any one of ⁇ 2> to ⁇ 3>, which is used for the treatment of at least one of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, and gout.
  • At least the synovial cell proliferation inhibitor according to ⁇ 1> is administered to treat at least one of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, and gout, It is a treatment method.
  • ⁇ 7> The treatment according to ⁇ 6>, wherein the pharmaceutical composition according to ⁇ 2> to ⁇ 5> is administered to treat at least one of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, and gout Is the method.
  • the conventional problems can be solved, and the proliferation of synovial cells can be suppressed without inducing apoptosis and without causing immune suppression. It is possible to provide an inhibitor, and a medicinal composition and a treatment method for treating a disease involving synovial cell proliferation without reducing resistance to infection.
  • FIG. 1 is a graph showing the effect of flavopiridol on the proliferation of synovial fibroblasts.
  • FIG. 2 is a histogram showing the effect of flavopiridol on cell cycle progression of synovial fibroblasts.
  • FIG. 3 is a graph showing changes in arthritis scores in CIA mice by intraperitoneal administration of flavopiridol.
  • FIG. 4 is a graph showing changes in arthritis scores in CIA mice by intraperitoneal administration of flavopiridol.
  • FIG. 5 is a tissue staining diagram and an X-ray photograph showing the effect of flavopiridol force on arthritis in mice.
  • A, D shows the hind limbs of CIA mice treated with DMSO only,
  • C and F represent hind limbs of CIA mice intraperitoneally administered with DMSO containing 2.5 mgZkg flavopiridol.
  • Fig. 6 shows the joints of RAG gene-deficient mice by intraperitoneal administration of KZBxN mouse serum. It is a graph which shows a flame point change.
  • FIG. 7 is a histogram showing the effect of flavopiridol on antibody response in CIA mice.
  • FIG. 8 is a histogram showing the effect of flavopiridol force on type 1 collagen-reactive T cell proliferation.
  • the synovial cell growth inhibitor of the present invention contains at least one of flavopiridol, which is a compound represented by the following structural formula (1), and a pharmaceutically acceptable salt thereof as an active ingredient.
  • the salt is not particularly limited and may be appropriately selected depending on the purpose. Examples thereof include inorganic salts and organic salts. Specific examples include hydrochlorides and hydrobromides. Sulfate, phosphate, acetate, oxalate, tartrate, kenate, maleate, and fumarate are preferred.
  • the production method of flavopiridol is not particularly limited, and a known method force can be appropriately selected according to the purpose.
  • a commercially available product may be used as flavopiridol.
  • the synovial cell proliferation inhibitor of the present invention can suppress the proliferation of synovial cells without inducing apoptosis.
  • the synovial cell proliferating agent can treat or prevent a disease in which the proliferation of synovial cells is involved in its pathological condition without the side effect of high safety.
  • This ability to inhibit the proliferation of synovial cells that does not induce apoptosis can be confirmed, for example, using a known cell proliferation analysis method such as measurement of BrdU incorporation or flow cytometry, and a cell cycle analysis method.
  • the fact that the synovial cell proliferation inhibitor of the present invention does not induce apoptosis can be confirmed by using known apoptosis detection methods such as SubGl analysis, TUNEL analysis, and agarose gel electrophoresis.
  • the synovial cell proliferation inhibitor has an action of suppressing proliferative synovitis by suppressing the proliferation of synoviocytes without inhibiting the proliferation and activity of lymphocytes. Treat or prevent cartilage degeneration and bone tissue destruction without inhibition.
  • This ability to suppress synovial cell proliferation without immunosuppression is achieved by, for example, transferring sera from mice that spontaneously develop arthritis (eg, KZBx N mice) to lymphocyte-deficient mice (eg, RAG gene-deficient mice).
  • mice that spontaneously develop arthritis eg, KZBx N mice
  • lymphocyte-deficient mice eg, RAG gene-deficient mice.
  • the mechanism of action of the synovial cell proliferation inhibitor of the present invention is lymph. It can be seen that this is not due to suppression of sphere proliferation.
  • the synovial cell proliferation inhibitor of the present invention has low cytotoxicity and high safety.
  • the molecular weight is small, for example, when administered to a living body, it is advantageous to immediately shift to a target site where synovial hyperplasia occurs.
  • synovial cell proliferation inhibitor of the present invention is suitable as an active ingredient of the medicinal composition of the present invention described below, and is also suitably used for the treatment method of the present invention described below.
  • the medicinal composition of the present invention contains at least the synovial cell proliferation inhibitor of the present invention and, if necessary, other components appropriately selected from known medium strengths.
  • Examples of the other components include a pharmaceutically acceptable carrier, and the carrier can be appropriately selected according to the dosage form of the medicinal composition without particular limitation.
  • the dosage form of the medicinal composition can be appropriately selected depending on the administration method without any particular restrictions. For example, oral solid preparations (tablets, coated tablets, granules, powders, capsules, etc.) , Oral solutions (internal solutions, syrups, elixirs, etc.), injections (solutions, suspensions, solid preparations for dissolution, etc.), suppositories, ointments, patches, gels, creams, powders for external use, Examples include sprays and inhaled powders.
  • Examples of the oral solid preparation include excipients to the synovial cell proliferation inhibitor, and additives such as binders, disintegrants, lubricants, coloring agents, and flavoring agents as necessary. And can be produced by a conventional method.
  • excipient examples include lactose, sucrose, sodium chloride salt, glucose, starch, calcium carbonate, kaolin, microcrystalline cellulose, silicic acid and the like.
  • the additive is not particularly limited and can be appropriately selected according to the purpose.
  • the binder include water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose. , Hydroxypropyl cellulose, hydroxypropinorestarch, methinoresenorelose, ethinoresenorelose, shellac, calcium phosphate, polybulurpyrrolidone and the like.
  • the disintegrant include dry starch and alginic acid.
  • examples of the flavoring 'flavoring agent include sucrose, orange peel, Kuen acid, and tartaric acid.
  • the oral liquid preparation can be produced by a conventional method, for example, by adding additives such as a flavoring agent, a buffering agent, and a stabilizer to the synovial cell proliferation inhibitor.
  • the additive is not particularly limited and can be appropriately selected according to the purpose.
  • the flavoring agent include sucrose, orange peel, citrate, tartaric acid, and the like.
  • the stabilizer include sodium quenate and the like, and examples of the stabilizer include tragacanth, gum arabic, and gelatin.
  • a pH regulator, a buffer, a stabilizer, an isotonic agent, a local anesthetic, etc. are added to the synovial cell proliferation inhibitor, and subcutaneous, muscle, etc. are added by a conventional method.
  • Intra and vein An internal injection can be produced.
  • Examples of the pH adjusting agent and the buffering agent include sodium citrate, sodium acetate, sodium phosphate and the like.
  • Examples of the stabilizer include sodium pyrosulfite, EDTA, thioglycolic acid, and thiolactic acid.
  • Examples of the isotonic agent include sodium chloride salt and glucose.
  • Examples of the local anesthetic include pro-in hydrochloride hydrochloride and lidocaine hydrochloride.
  • the synovial cell proliferation inhibitor As the suppository, the synovial cell proliferation inhibitor, a known suppository formulation carrier, for example, polyethylene glycol, lanolin, cocoa butter, fatty acid triglyceride and the like, and TWEEN (TWEEN) as necessary. : A registered trademark) and the like, and then can be produced by a conventional method.
  • a known suppository formulation carrier for example, polyethylene glycol, lanolin, cocoa butter, fatty acid triglyceride and the like, and TWEEN (TWEEN) as necessary. : A registered trademark) and the like, and then can be produced by a conventional method.
  • the ointment can be produced by mixing a known base, stabilizer, wetting agent, preservative and the like with the synovial cell proliferation inhibitor and mixing them by a conventional method.
  • the base include liquid paraffin, white petrolatum, honey beeswax, otatildodecyl alcohol, paraffin and the like.
  • the preservative include methyl noxybenzoate, ethyl paraoxybenzoate, and propyl noraoxybenzoate.
  • the patch can be produced, for example, by applying a cream, gel, paste or the like as the ointment to a known support by a conventional method.
  • the support include cotton, suf, woven fabric made of chemical fiber, non-woven fabric, soft vinyl chloride, polyethylene, polyurethane and other films, and foam sheets.
  • the content of the synovial cell proliferation inhibitor in the pharmaceutical composition can be appropriately selected depending on the symptom of the patient to whom the dosage form is administered, but is usually per dosage unit.
  • the oral preparation about 1-1, OOOmg is preferred.
  • about 0.1-50Omg is preferred, and in the case of the suppository, about 5-1, OOOmg is preferred.
  • the dosage of the pharmaceutical composition is a force that can be appropriately selected according to the patient's symptoms, weight, age, sex, etc. Usually, about 0.1 to 5, OOOmg per day for an adult is preferable, ⁇ : L, more preferred than OOOmg power! / ⁇ .
  • the daily dose is preferably administered once or divided into 2 to 4 times.
  • the medicinal composition of the present invention is suitable as a therapeutic or prophylactic agent for diseases in which the proliferation of synovial cells is involved in its pathology, such as anti-rheumatoid arthritis agents, anti-degenerative arthropathy agents, Suitable as anti-psoriatic arthritis agent and anti-gout agent.
  • the therapeutic method of the present invention comprises administering at least the synovial cell proliferation inhibitor and rheumatoid arthritis.
  • the method for administering the synovial cell proliferation inhibitor or the pharmaceutical composition can be appropriately selected according to the dosage form and the like, which are not particularly limited.
  • the effect of the synovial cell proliferation inhibitor of the present invention on the proliferation and cell cycle progression of the synovial fibroblasts was evaluated by the following method.
  • Rheumatoid synovial fibroblasts (RSF) in human rheumatoid synovial fibroblasts (RSF) have undergone total joint replacement or synovectomy at Tokyo Medical and Dental University Hospital or National Hospital Organization Shimotsu Hospital. RA) The patient's synovial tissue strength was collected and prepared.
  • Rheumatoid arthritis (RA) is a standard of the American College of Rheumatology (Arnett et al .; Arthritis Rheum. 1988;
  • mice synovial fibroblasts from the knee joints of CIA mice immunized with type II collagen and induced arthritis (see Example 2 below) Synovial tissue force was also collected and prepared (see Abad et al .; J Immunol 2001; 167 (6): 3182-31 89).
  • RSF and MSF were cultured in DMEM medium (Sigma) supplemented with L-glutamine, penicillin, streptomycin and 10% urine fetal serum (Sigma), respectively.
  • Flavopyridol (0.01-10 M) or 5% glucose-containing 1 Ommol / L citrate buffer (pH 4) well was added as a control. After 24 hours, bromodexuridine (BrdU) was added and the culture was continued. After 20 hours, the incorporated BrdU was quantified using a Brd U Cell Proliferation ELISA kit (Exalpha Biologicals). The results are shown in Figure 1.
  • Figure 1 shows the percentage of BrdU uptake in flavopiridol-added cocoon at each concentration when the amount of BrdU incorporation in flavopiridol-free cocoon (control) is 100%. . Average values of 3 wells are shown with error bars indicating standard deviation (SD). Representative results from three independent experiments are shown.
  • the cell cycle analysis of the RSF and MSF was performed as follows.
  • the RSF and MSF were treated in the same manner as described above in the presence of the flavopiridol (2.5 mol / L) or in the presence of 10 mmol / L citrate buffer (pH 4) containing 5 o / o glucose as a control.
  • the cells were washed with phosphate buffered saline (PBS) and resuspended in 0.15% TritonXZPBS.
  • the DNA content was stained using a FACS caliber flow cytometer (Becton Dickinson) after staining with propidium iodide (50 ⁇ g / ml). The result is shown in figure 2.
  • FIG. 2 shows a histogram of DNA content and a percentage group indicating the proportion of cells in each cell cycle stage. Representative results from three independent experiments are shown.
  • flavopiridol inhibited the proliferation of RSF and MSF in a dose-dependent manner (Fig. 1). At all concentrations tested, phenotypic cell death due to the addition of the flavopiridol was not observed.
  • flavopiridol increased the number of cells in the GOZG1 phase without increasing the number of sub-G1 groups, which is an index of apoptosis, in any type of cells, that is, Led to cell cycle arrest in the G1 phase ( Figure 2).
  • the synovial cell proliferation inhibitor of the present invention has an action capable of strongly suppressing the proliferation of synovial fibroblasts without inducing apoptosis.
  • Collagen-induced arthritis in mice is a disease in which synovitis with the proliferation of synovial cells occurs as a result of autoimmunity to type II collagen, and the joint is destroyed like rheumatoid arthritis.
  • the arthritis model mouse was prepared by the following method, and the suppression of arthritis by the synovial cell proliferation inhibitor of the present invention was evaluated.
  • the arthritis model mouse was intraperitoneally administered with flavopiridol dissolved in 0.01% DMSO for 10 consecutive days from 4 days after booster immunization (25 days after the first immunization).
  • the administered group was divided into two groups, and the dose of flavopiridol was set to 1 mg / kg or 2.5 mg Zkg, respectively.
  • DMSO alone was administered intraperitoneally in an equal amount.
  • the arthritis score was analyzed statistically by Student's t test.
  • the degree of swelling of the joints of the CIA mice administered with the abdominal cavity was quantified by measuring the thickness of the hind limbs and the width of the ankles using a micrometer (Ozaki Seisakusho).
  • the arthritis model mice prepared in the same manner as in Example 2 were treated twice a week for 5 weeks from 3 days after booster immunization (24 days after the first immunization) (28, 34, 38, 42, 4 from the first immunization). 5, 48, 52, 55, 59, and 62 days later) Flavopiridol dissolved in 0.01% DMSO was administered intraperitoneally. There are 3 administration groups, with flavopiridol doses of lmg / kg and 2.5 mg / kg, and 2.5 mg / kg for which administration was discontinued 34 days after the first immunization. did. In addition, as a comparison target group, DMSO alone was administered intraperitoneally in an equal amount. The results of evaluating the degree of arthritis development in the same manner as above are shown in FIG.
  • Fig. 4 also shows the average values of 7 mice with error bars indicating standard deviation (SD) (*: p ⁇ 0.05, water: p ⁇ 0.01, water: p ⁇ 0. 001).
  • FIG. 5A-C light microscope image (HE staining)
  • Fig. 5D- F light microscope image X-rays
  • cyst formation severe bone with joint stiffness seen in DMSO-only mice It was found that destruction (FIGS. 5A, D) was suppressed in a dose-dependent manner with flavopiridol (FIGS. 5B, C, E, F).
  • mice lacking the RAG gene have no immune response due to lymphocytes due to lack of lymphocytes.However, when mice with model mice (KZBx N) that spontaneously develop arthritis very similar to rheumatoid arthritis (KZBx N serum) are administered, It is known that the proliferation of membrane cells is promoted and arthritis is caused. Using this model mouse, the inhibition of arthritis by the synovial cell proliferation inhibitor of the present invention was evaluated.
  • An arthritis model was prepared by intraperitoneally administering 300 L of serum of KZBxN mice to RAG gene-deficient mice (9-10 weeks old, RAG2ZB6 KO, C57BLZ6 genetic background).
  • flavopiridol dissolved in DMSO was administered intraperitoneally as a synoviocyte growth inhibitor for 10 consecutive days.
  • the administration group was divided into two groups, and the dose of flavopiridol was 1 mg / kg or 2.5 mgZkg, respectively.
  • DMSO alone was given an equivalent amount of abdominal cavity.
  • the degree of arthritis was improved in the mice administered with the flavopiridol compared to the mice administered only with DMSO not containing the flavopiridol.
  • the improvement was dependent on the dose. From this, it was also found that the suppression of proliferative arthritis was not due to the suppression of immune reactions such as the inhibition of lymphocyte activity or the suppression of proliferation of the synovial cell proliferation inhibitor of the present invention. .
  • mice were administered to model mice in which arthritis was induced in the same manner as in Example 2, and the administration start date (day 0, immediately before administration), day 11 after administration, and after administration 39 On the day, antibody responses of mouse subclasses (IgG1, IgG2a, IgG2b) were measured by the following method.
  • Ushi type II collagen diluted with PBS was placed in a 96-well plate and allowed to stand at 4 ° C.
  • the 96-well plate was washed with 0.05% Tween20-containing PBS, and then washed with 2% Blocking was carried out with PBS containing serum serum albumin to prepare 96-well plates coated with ushi type II collagen.
  • the antibody response is measured by placing a diluted serum solution collected from the mouse in a 96-well plate coated with the Ushi type II collagen and reacting at room temperature for 2 hours, and then the 96-well plate. Next, peroxidase-conjugated anti-mouse IgGl, IgG2a, or IgG2b antibody (manufactured by Zymed) is added and reacted, and these are developed with TMBZ (3, 3, 5, 5, 1 Tetramethylbenzidine) substrate. The measurement was performed by measuring the absorbance at a wavelength of 450 nm.
  • mice were immunized with type II collagen. Simultaneously with the initiation of immunization, flavopiridol 5 mg Zkg was administered intraperitoneally for 5 consecutive days, separated by 1 day, and again administered for 5 consecutive days. As a control, mice not administered with flavopiridol were also prepared (type I collagen immunization only). On the 12th day after the start of immunization, the spleen was removed, and the cells were seeded on 96 well plates with 200,000 cell Z well and each amount (0, 4, 20, 100 ⁇ & ml) of type II collagen for 72 hours. After culture, BrdU was added and further cultured. 17 hours Subsequently, the incorporated BrdU was quantified by ELISA to examine the proliferation of type II collagen-reactive T cells. The results are shown in FIG.
  • FIG. 8 shows the percentage of BrdU incorporation in each group when the amount of BrdU incorporation was 100% when no type II collagen was added during culture (0 gZml).
  • the synovial cell proliferation inhibitor comprising flavopiridol as an active ingredient and the medicinal composition comprising the synovial cell proliferation inhibitor as an active ingredient of the present invention can increase synovial cell proliferation when administered.
  • by administering the synovial cell proliferation inhibitor and the medicinal composition it is possible to prevent or treat diseases in which synovial cell proliferation is involved in pathological conditions without suppressing immunity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un inhibiteur de la prolifération de cellules synoviales qui n’induit pas d’apoptose ou d’immunosuppression et est capable d’inhiber la prolifération d’une cellule synoviale. L’invention concerne aussi une composition pharmaceutique ou un procédé thérapeutique capable de traiter une maladie impliquant une prolifération de cellules synoviales, sans pour autant réduire la résistance vis-à-vis d’une infection. L’invention décrit un inhibiteur de la prolifération de cellules synoviales comprenant au moins un flavopiridol (dénomination IUPAC : alvocidib), qui est un composé de formule structurale (1), ainsi qu’un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif ; une composition pharmaceutique comprenant au moins ledit inhibiteur de la prolifération de cellules synoviales; et un procédé thérapeutique comprenant au moins l’administration de l’inhibiteur de la prolifération de cellules synoviales.
PCT/JP2006/314287 2005-07-19 2006-07-19 Inhibiteur de la proliferation de cellules synoviales WO2007010946A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005-209111 2005-07-19
JP2005209111A JP2008255008A (ja) 2005-07-19 2005-07-19 滑膜細胞増殖抑制剤

Publications (1)

Publication Number Publication Date
WO2007010946A1 true WO2007010946A1 (fr) 2007-01-25

Family

ID=37668822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/314287 WO2007010946A1 (fr) 2005-07-19 2006-07-19 Inhibiteur de la proliferation de cellules synoviales

Country Status (2)

Country Link
JP (1) JP2008255008A (fr)
WO (1) WO2007010946A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018039324A1 (fr) 2016-08-23 2018-03-01 Eisai R&D Management Co., Ltd. Polythérapies pour le traitement du carcinome hépatocellulaire
WO2018170447A1 (fr) 2017-03-16 2018-09-20 Eisai R&D Management Co., Ltd. Polythérapies pour le traitement du cancer du sein

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6049455B2 (ja) * 2009-05-18 2016-12-21 ザ ユニバーシティ オブ ホンコンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｈｏｎｇ Ｋｏｎｇ 炎症性関節炎を治療するための組成物および方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603137A (en) * 1983-08-12 1986-07-29 Hoechst Aktiengesellschaft Immunosuppressive chromone alkaloid
WO2001021793A1 (fr) * 1999-09-22 2001-03-29 Nobuyuki Miyasaka TRAITEMENTS CONTRE LES RHUMATISMES A BASE DE p21?Cip1¿
JP2002535356A (ja) * 1999-02-01 2002-10-22 アベンティス・ファーマスーティカルズ・インコーポレイテツド ４−ｈ−１−ベンゾピラン−４−オン誘導体の平滑筋細胞増殖インヒビターとしての使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603137A (en) * 1983-08-12 1986-07-29 Hoechst Aktiengesellschaft Immunosuppressive chromone alkaloid
JP2002535356A (ja) * 1999-02-01 2002-10-22 アベンティス・ファーマスーティカルズ・インコーポレイテツド ４−ｈ−１−ベンゾピラン−４−オン誘導体の平滑筋細胞増殖インヒビターとしての使用
WO2001021793A1 (fr) * 1999-09-22 2001-03-29 Nobuyuki Miyasaka TRAITEMENTS CONTRE LES RHUMATISMES A BASE DE p21?Cip1¿

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEDLACEK H.H. ET AL.: "Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 9, no. 6, 1996, pages 1143 - 1168, XP002103774 *
TANIGUCHI ET AL.: "Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis", NATURE MEDICINE, vol. 5, no. 7, 1999, pages 760 - 767, XP000993540 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018039324A1 (fr) 2016-08-23 2018-03-01 Eisai R&D Management Co., Ltd. Polythérapies pour le traitement du carcinome hépatocellulaire
WO2018170447A1 (fr) 2017-03-16 2018-09-20 Eisai R&D Management Co., Ltd. Polythérapies pour le traitement du cancer du sein
US11083722B2 (en) 2017-03-16 2021-08-10 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
EP4218820A2 (fr) 2017-03-16 2023-08-02 Eisai R&D Management Co., Ltd. Polythérapies pour le traitement du cancer du sein

Also Published As

Publication number Publication date
JP2008255008A (ja) 2008-10-23

Similar Documents

Publication Publication Date Title
US11357760B2 (en) Method of treating liver fibrosis
AU2020203867A1 (en) Cenicriviroc for the treatment of fibrosis
US20050163764A1 (en) Treatment with agonists of toll-like receptors
TWI746449B (zh) 使用阿吡莫德治療癌症之方法
KR20170003527A (ko) 경구 투여용 펜토산 폴리설페이트 염의 조성물
JP7530116B2 (ja) エムトール信号伝達抑制剤を有効成分として含む癌の予防又は治療用薬剤学的組成物
US9364459B2 (en) 3-(indolyl)- or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
CN117750961A (zh) 毛蕊异黄酮和/或毛蕊异黄酮葡萄糖苷治疗自身免疫性疾病的用途
JP2019511495A (ja) ＧＳＫ３β阻害薬チデグルシブによるＣＤＫＬ５障害の治療
WO2007010946A1 (fr) Inhibiteur de la proliferation de cellules synoviales
KR20210056931A (ko) 피리메타민을 유효성분으로 포함하는 면역 관련 질환의 치료 또는 예방용 약학 조성물
CN115068478B (zh) 磷酸萘酚喹在制备治疗自身免疫性疾病药物中的应用
CN104302293B (zh) 用于压力性尿失禁的预防剂和/或治疗剂
CN102793693A (zh) 伏立诺他在制备治疗自身免疫及炎症性疾病药物方面的应用
JP2023164916A (ja) 一部の肉腫の治療に使用するためのｉｌ－８阻害薬
JP7406192B2 (ja) 線維症治療薬
JP7367056B2 (ja) 粘土鉱物複合体を含む炎症性大腸炎の予防、改善及び治療用組成物、組成物の製造方法、及び炎症性大腸炎の改善及び治療方法
CN116549632B (zh) 抗Lingo-1抗体Opicinumab的新用途及针对新用途的药物
US20250136661A1 (en) Pharmaceutical composition comprising adipose tissue-derived extracellular vesicle and biologic and use of pharmaceutical composition for treating arthritis
CN111514298B (zh) 质子泵抑制剂与pd-1轴结合拮抗剂的组合及其用途
JP2007326824A (ja) 滑膜細胞増殖抑制剤、並びにこれを利用した薬用組成物及び治療方法
WO2023143446A1 (fr) Compositions et méthodes permettant de traiter un choc cytokinique
US20250099487A1 (en) Composition for preventing or treating pulmonary fibrosis, comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient
EP4353234A1 (fr) Utilisation d'un composé pyrrolopyrimidine
WO2023203022A1 (fr) Traitement de dermatoses neutrophiles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06768313

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载